Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02032823|
Recruitment Status : Active, not recruiting
First Posted : January 10, 2014
Last Update Posted : May 23, 2019
Breast International Group
Frontier Science & Technology Research Foundation, Inc.
Myriad Genetic Laboratories, Inc.
Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Active, not recruiting|
|Estimated Primary Completion Date :||November 30, 2020|
|Estimated Study Completion Date :||November 27, 2028|